Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.67 |
| ▸ | GRM5 | P41594 | 10/20 | 0.63 |
| ▸ | GRM1 | Q13255 | 10/20 | 0.63 |
| ▸ | HTR6 | P50406 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4859866 | 1.00 | PDK4 (0.67) | PDK4GRM5GRM1HTR6NAMPT | |
| SCHEMBL19818315 | 0.89 | PDK4 (0.65) | PDK4GRM5GRM1HTR6NAMPT | |
| SCHEMBL29691225 | 0.88 | PDK4 (0.64) | PDK4GRM5GRM1HTR6NAMPT | |
| SCHEMBL13993115 | 0.88 | PDK4 (0.64) | PDK4GRM5GRM1HTR6NAMPT | |
| SCHEMBL25044030 | 0.88 | PDK4 (0.54) | PDK4GRM5GRM1HTR6NAMPT | |
| SCHEMBL19297155 | 0.87 | PDK4 (0.60) | PDK4GRM5GRM1HTR6NAMPT | |
| SCHEMBL24186499 | 0.87 | PDK4 (0.60) | PDK4GRM5GRM1HTR6NAMPT | |
| SCHEMBL23228626 | 0.86 | PDK4 (0.65) | PDK4GRM5GRM1HTR6NAMPT | |
| SCHEMBL4538783 | 0.86 | CDK9 (0.55) | PDK4GRM5GRM1 | |
| SCHEMBL4013425 | 0.85 | PDE10A (0.62) | PDK4GRM5GRM1HTR6NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| CN-119698412-A | 5-HT2A receptor agonist, and preparation method and application thereof | 上海翊石医药科技有限公司 | 2025-03-25 | — | — | CN | disclosed |
| WO-2025021120-A1 | 5-HT2A RECEPTOR AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2025-01-30 | — | — | WO | disclosed |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | CYP4A22, ALOX5, ALOX15 | PDK4 1189/4885GRM5 1092/4885GRM1 2182/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | PDK4 1189/4885GRM5 1092/4885GRM1 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.